CLVT · Clarivate PLC
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. Clarivate reaffirmed its full-year 2026 outlook, expecting ~200 bps adjusted EBITDA margin expansion and ~$900M of debt paydown, while Q2 net loss widened to $268.6M due to a $221.7M non-cash goodwill impairment linked to the pending Life Sciences & Healthcare divestiture.
- + Full-year 2026 outlook reaffirmed with adjusted EBITDA margin guided to expand ~200 bps
- + Free cash flow guided at low end of $365M–$435M range with plan to retire ~$900M of debt using FCF and LS&H divestiture proceeds
- + H1 adjusted EBITDA margin expanded 90 bps to 41.6% on recurring growth and cost discipline
- + Total debt reduced by $218.4M in H1 via opportunistic repurchases at a discount to par
- + Organic ACV grew 1.5% with H1 subscription organic growth up 60 bps YoY to 1.2%
- − Q2 GAAP net loss widened to $268.6M ($0.42/share) on a $221.7M non-cash goodwill impairment tied to the LS&H divestiture
- − Q2 Adjusted EBITDA declined 5.5% to $247.2M, with H1 free cash flow down 23.5% to $122.9M
- − Full-year 2026 free cash flow guided to be flat YoY at low end of range due to ~$70M of one-time LS&H transaction costs
- − H1 operating cash flow declined 18.8% to $233.4M driven by lower EBITDA and higher working capital use
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Information Technology Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLVT
this stock
Clarivate PLC
|
$1.08B | -50.0% | +0.6% | — | 7.6% |
|
IBM
International Business Machines Corp
|
$212.46B | -25.8% | +7.6% | 20.0 | 2.4% |
|
ACN
Accenture plc
|
$116.59B | -31.7% | +7.4% | 14.0 | 3.7% |
|
INFY
Infosys Ltd
|
$42.53B | -39.6% | — | — | 3.1% |
|
CTSH
Cognizant Technology Solutions Corp
|
$27.26B | -30.8% | +7.0% | 12.5 | 7.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLVT | -8.7% | -18.1% | -23.4% | -18.5% | -50.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -8.1% | -18.3% | -35.6% | -18.0% | -61.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.